Ignite Creation Date:
2024-05-05 @ 4:42 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00299988
Status:
TERMINATED
Last Update Posted:
2019-12-11
First Post:
2006-03-03
Brief Title:
Phase II Study of Intravenous Immunoglobulin IVIg for Alzheimers Disease
Sponsor:
Weill Medical College of Cornell University
Organization:
Weill Medical College of Cornell University
Study Overview
Official Title:
A Placebo-controlled Randomized Double-Blind Phase II Clinical Study of Gammagard Intravenous Immunoglobulin IVIg for Treatment of Mild to Moderate Alzheimers Disease
Status:
TERMINATED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The overall goal of this double-blind Phase II study is to evaluate the safety efficacy and biological mechanisms of action of Intravenous Immunoglobulin IVIg in the treatment of mild to moderate stage Alzheimers disease AD IVIg contains antibodies against the amyloid beta protein that is the central component of the AD senile plaque It is hypothesized that IVIg treatment will reduce the levels of beta amyloid in the brain and improve cognitive abilities relative to placebo A total of 24 patients with mild to moderate AD capable of giving informed consent will be randomly assigned to receive either IVIg 16 patientsor saline placebo 8 patients for six months This study includes comparison of four dosing regimens of IVIg Cognitive behavioral and functional measures will be collected at baseline three months and six months of treatment Plasma samples will be collected before and after infusions Subjects will undergo a lumbar puncture before and after the six months of treatment for cerebrospinal fluid CSF biomarker analyses In addition Positron Emission Tomography PET imaging substudies will be performed at two time points during the study Following the initial 6 month placebo-controlled period all participants have the opportunity to receive IVIg for an additional 12 month period in an extension study
Detailed Description:
Abnormal processing of the beta-amyloid protein is thought to be an early and causative event in the pathogenesis of Alzheimers disease AD Immunotherapy targeting beta amyloid Aβ has demonstrated a remarkable capacity to arrest and even reverse elements of AD brain pathology Intravenous Immunoglobulin IVIg is a medication obtained from the pooled plasma of healthy human blood donors that contains natural anti-amyloid antibodies and exhibits potent central nervous system anti-inflammatory properties IVIg has been FDA-approved and used for more than 25 years in patients with a variety of immune deficiency and autoimmune diseases and has an established safety record but is not FDA-approved for the treatment of AD
A total of 24 patients males and females 50 years of age and older with mild to moderate Alzheimers disease AD will be enrolled in this research study To be eligible patients must meet the National Institute of Neurological and Communicative Disorders and StrokeAlzheimers Disease and Related Disorders Association NINCDS-ADRDA criteria for probable AD After written informed consent is obtained subjects will go through a screening process to determine if he or she meets the inclusion criteria Screening procedures include medical history blood and urine tests neurologic exam chest x-ray and MRI Women who want to take part in this study must either be post-menopausal surgically sterilized or agree to avoid becoming pregnant during the entire period of their participation in this study
To be eligible for this research study patients must be taking a stable dose of an approved AD medication for at least 3 months prior to entering this study or be unable to take these medications The design of this protocol is that of an add-on study and we will recommend patients continue to take any FDA-approved AD medications they are taking at study entry
Subjects participation in the study will last approximately 19 months including screening and baseline procedures treatment with study drug and a follow-up visit 1 ½ months after finishing treatment plus a visit for blood tests 6 months after the last infusion in the study This research study requires that the patient have another person such as a spouse child other relative close friend aide or other professional caregiver who will accompany the patient to each clinic visit
Subjects will be randomized to a treatment group for 6 months of infusions of IVIg or placebo The treatment groups compare different doses and frequencies of treatment Patients will have a 33 chance of receiving placebo
Blood will be obtained from subjects every two weeks and examined in our research laboratories to obtain more information about IVIgs biological effects Cerebrospinal fluid will be obtained by lumbar puncture twice over the course of the study for the same purpose Patients will be asked to allow a portion of a blood sample to be used for Apolipoprotein E APOE testing and banked for genetic research testing related to AD and aging but do not have to participate in the testing or allow their blood sample to be stored in order to take part in the study
Cognitive testing will be carried out at baseline and every three months over a period of 18 months Results of cognitive testing will constitute the primary endpoint of this study Positron Emission Tomography PET imaging substudies will be performed at two time points during the study Safety laboratories and assessments will be carried out at regular intervals Subjects will not be responsible for any research study-related costs but will be responsible for the costs of evaluations required to establish diagnosis
A total of 24 patients males and females 50 years of age and older with mild to moderate Alzheimers disease AD will be enrolled in this research study To be eligible patients must meet the National Institute of Neurological and Communicative Disorders and StrokeAlzheimers Disease and Related Disorders Association NINCDS-ADRDA criteria for probable AD After written informed consent is obtained subjects will go through a screening process to determine if he or she meets the inclusion criteria Screening procedures include medical history blood and urine tests neurologic exam chest x-ray and MRI Women who want to take part in this study must either be post-menopausal surgically sterilized or agree to avoid becoming pregnant during the entire period of their participation in this study
To be eligible for this research study patients must be taking a stable dose of an approved AD medication for at least 3 months prior to entering this study or be unable to take these medications The design of this protocol is that of an add-on study and we will recommend patients continue to take any FDA-approved AD medications they are taking at study entry
Subjects participation in the study will last approximately 19 months including screening and baseline procedures treatment with study drug and a follow-up visit 1 ½ months after finishing treatment plus a visit for blood tests 6 months after the last infusion in the study This research study requires that the patient have another person such as a spouse child other relative close friend aide or other professional caregiver who will accompany the patient to each clinic visit
Subjects will be randomized to a treatment group for 6 months of infusions of IVIg or placebo The treatment groups compare different doses and frequencies of treatment Patients will have a 33 chance of receiving placebo
Blood will be obtained from subjects every two weeks and examined in our research laboratories to obtain more information about IVIgs biological effects Cerebrospinal fluid will be obtained by lumbar puncture twice over the course of the study for the same purpose Patients will be asked to allow a portion of a blood sample to be used for Apolipoprotein E APOE testing and banked for genetic research testing related to AD and aging but do not have to participate in the testing or allow their blood sample to be stored in order to take part in the study
Cognitive testing will be carried out at baseline and every three months over a period of 18 months Results of cognitive testing will constitute the primary endpoint of this study Positron Emission Tomography PET imaging substudies will be performed at two time points during the study Safety laboratories and assessments will be carried out at regular intervals Subjects will not be responsible for any research study-related costs but will be responsible for the costs of evaluations required to establish diagnosis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None